Market Cap 1.29B
Revenue (ttm) 117.00M
Net Income (ttm) -307.00M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -262.39%
Debt to Equity Ratio 0.08
Volume 331,600
Avg Vol 695,198
Day's Range N/A - N/A
Shares Out 91.51M
Stochastic %K 25%
Beta 0.87
Analysts Strong Sell
Price Target $34.20

Latest News on RCUS

Arcus: Excellent Pipeline And Collaborations, Cash Runway

Jan 13, 2025, 8:00 AM EST - 4 days ago

Arcus: Excellent Pipeline And Collaborations, Cash Runway


Arcus Biosciences Announces New Employment Inducement Grants

Dec 24, 2024, 4:05 PM EST - 24 days ago

Arcus Biosciences Announces New Employment Inducement Grants


Arcus Biosciences, Inc. (RCUS) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 11:39 PM EST - 2 months ago

Arcus Biosciences, Inc. (RCUS) Q3 2024 Earnings Call Transcript


Arcus Biosciences: Getting Too Cheap To Ignore (Reiterate Buy)

Aug 9, 2024, 5:31 PM EDT - 5 months ago

Arcus Biosciences: Getting Too Cheap To Ignore (Reiterate Buy)


Arcus Biosciences, Inc. (RCUS) Q2 2024 Earnings Call Transcript

Aug 9, 2024, 5:21 PM EDT - 5 months ago

Arcus Biosciences, Inc. (RCUS) Q2 2024 Earnings Call Transcript


Arcus Biosciences, Inc. (RCUS) Q1 2024 Earnings Call Transcript

May 8, 2024, 9:55 PM EDT - 9 months ago

Arcus Biosciences, Inc. (RCUS) Q1 2024 Earnings Call Transcript


Arcus Biosciences, Inc. (RCUS) Q4 2023 Earnings Call Transcript

Feb 22, 2024, 2:08 AM EST - 11 months ago

Arcus Biosciences, Inc. (RCUS) Q4 2023 Earnings Call Transcript


Arcus Biosciences' Oncology Odyssey: The Domvanalimab Journey

Nov 20, 2023, 2:19 PM EST - 1 year ago

Arcus Biosciences' Oncology Odyssey: The Domvanalimab Journey


Arcus Biosciences: Huge Cash, Gilead Deal, Not A Lot Of Data

Aug 29, 2023, 2:40 PM EDT - 1 year ago

Arcus Biosciences: Huge Cash, Gilead Deal, Not A Lot Of Data